Mumbai, Oct. 13 -- Zydus Lifesciences and Formycon AG (Formycon), an independent developer of biosimilars, today jointly announced that the US Food and Drug Administration (USFDA) has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda(R)1 (pembrolizumab).

Published by HT Digital Content Services with permission from Capital Market....